Imunon counsel sells 2,525 shares at about $1.56

Imunon, Inc. (IMNN) reported insider equity activity by General Counsel and Corporate Secretary Susan Eylward.

Rhea-AI Filing Summary

Imunon, Inc. (IMNN) reported insider equity activity by General Counsel and Corporate Secretary Susan Eylward. On 2026-08-28, she received 2,525 shares of common stock at $1.60 per share as stock granted in lieu of a portion of base salary. On 2026-08-31, she sold 2,525 shares of common stock at a weighted average price of $1.5643 per share, with individual sale prices ranging from $1.55 to $1.58 per share. Resulting share holdings are not stated in this report.

Insider Trade Summary

Net Seller: 2,525 shares

Net Sell 2 txns

Insider Eylward Susan

Role General Counsel and Corp Sec

Sold 2,525 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock F2	2,525	$1.5643	$4K
Grant/Award	Common Stock F1	2,525	$1.60	$4K

Holdings After Transaction: Common Stock — 2,896 shares (Direct)

Footnotes (2)

1. F1. Stock granted in lieu of cash for portion of base salary
2. F2. Reflects a weighted average sale price of $1.5643 per share, at prices ranging from $1.55 to $1.58 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.

Key Figures

Shares awarded: 2,525 shares of Common Stock Award price per share: $1.60 per share Shares sold: 2,525 shares of Common Stock +2 more

5 metrics

Shares awarded 2,525 shares of Common Stock Grant in lieu of cash for portion of base salary on 2026-08-28

Award price per share $1.60 per share Stock granted on 2026-08-28

Shares sold 2,525 shares of Common Stock Sale on 2026-08-31

Weighted average sale price $1.5643 per share Sale on 2026-08-31; individual prices from $1.55 to $1.58

Net buy/sell shares -2,525 shares Transaction summary across reported transactions

Key Terms

weighted average sale price, in lieu of cash, grant, award, or other acquisition, open market or private transaction

4 terms

weighted average sale price financial

"Reflects a weighted average sale price of $1.5643 per share"

in lieu of cash financial

"Stock granted in lieu of cash for portion of base salary"

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition"

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did IMNN’s General Counsel report in this Form 4?

Susan Eylward, General Counsel and Corporate Secretary of Imunon, Inc. (IMNN), reported two transactions: an award of 2,525 shares of common stock on 2026-08-28 in lieu of a portion of base salary, and a sale of 2,525 shares on 2026-08-31.

At what prices were the IMNN shares sold by the insider on 2026-08-31?

On 2026-08-31, the insider sold 2,525 IMNN shares at a weighted average price of $1.5643 per share. The reported sale prices ranged from $1.55 to $1.58 per share across individual trades.

What was the nature of the IMNN share award reported on 2026-08-28?

On 2026-08-28, the insider received 2,525 shares of IMNN common stock at $1.60 per share. The footnote states this stock was granted in lieu of cash for a portion of the insider’s base salary.

Does this IMNN insider transaction involve a Rule 10b5-1 trading plan?

The report indicates the Rule 10b5-1 checkbox is not affirmed, and the footnotes do not mention a trading plan. The transactions are therefore not identified as being executed under a pre-arranged Rule 10b5-1 plan.

How many IMNN shares did the insider buy or sell net in these transactions?

Across the reported transactions, the insider had an award of 2,525 shares and a sale of 2,525 shares, for a net reported change in common stock position of 0 shares in this Form 4’s transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:08 PM EDT Accepted by SEC EDGAR 09/01/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eylward Susan

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Corp Sec

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/28/2026		A		2,525(1)	A	$1.6	5,421	D
Common Stock	08/31/2026		S		2,525	D	$1.5643(2)	2,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of base salary

2. Reflects a weighted average sale price of $1.5643 per share, at prices ranging from $1.55 to $1.58 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.

	/s/ Susan Eylward	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)